Aurinia Pharmaceuticals Inc (AUPH)
NASDAQ · Manufacturing · Pharmaceutical preparations
$16.44−$0.1550 (−0.93%) on the dayAs of the close; data may be delayed.
AUPH price, last 12 months
Key stats
- Previous close
- $16.60
- Open
- $16.60
- Day range
- $16.31 – $16.78
- 52-week range
- $10.34 – $19.25
- Volume
- 740.9K
- Avg volume (20 days)
- 815.4K
- Market cap
- $2.2B
Performance
1W−2.7%
1M−0.6%
3M−4.6%
6M+12.6%
YTD+3.1%
1Y+27.6%
vs S&P 500, 1Y+10.9 pts
Technicals and fundamentals
About Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $2.2B